A review of preclinical evidence shows the endocannabinoid system plays distinct roles in alcohol addiction (through CB1 receptors in reward circuits) and fetal alcohol spectrum disorders (through developmental ECS disruption), suggesting different therapeutic targets for each.
Addiction neuroscientists, developmental biologists, and pharmacologists developing ECS-targeted treatments.
Distinct ECS functions
What the researchers found
The ECS plays a major role in the motivation to abuse alcohol, with chronic alcohol consumption modulating endocannabinoids and CB1 receptor expression in brain addiction circuits. Separately, the ECS has a distinct function in the development of fetal alcohol spectrum disorders, suggesting these are mechanistically separable processes.
Why it matters
By distinguishing the ECS roles in alcohol addiction versus fetal alcohol effects, this review clarifies that different therapeutic strategies may be needed for each condition rather than a one-size-fits-all approach to ECS manipulation.
The numbers in context
CB1 receptors are present in inhibitory and excitatory presynaptic terminals. CB2 receptors found in neuronal subpopulations, microglia, and astrocytes at both pre- and postsynaptic terminals. Chronic alcohol modulates eCBs and CB1R expression in addiction circuits.
How the study worked
Comprehensive review assessing recent literature on the function of the endocannabinoid system in alcohol abuse disorders, covering both adult addiction pathways and developmental effects.
What this study cannot tell us
Primarily based on preclinical data. The distinction between "distinct functions" may be more nuanced than presented. Clinical applications of ECS-targeted therapies for alcohol disorders remain theoretical.
How to read the evidence
Rated moderate because the review synthesizes substantial preclinical evidence with a clear mechanistic framework.
When this study was published
Published in 2019 in the British Journal of Pharmacology.
The bigger picture
The distinction between ECS roles in adult addiction versus developmental disorders suggests the system is not monolithic. Different components of the ECS may need to be targeted differently depending on whether the goal is treating addiction or preventing developmental harm.
Questions still open
- Can ECS-targeted therapies be developed that address alcohol addiction without affecting developmental pathways? Are the distinct ECS functions in addiction versus FASD mediated by different receptor subtypes or different brain regions?
Common questions
How does the endocannabinoid system relate to alcohol addiction?
Is the ECS involvement the same in fetal alcohol effects?
Read the original research
Distinct functions of endogenous cannabinoid system in alcohol abuse disorders.
British journal of pharmacology, 176(17), 3085-3109
Citation
Basavarajappa, Balapal S; Joshi, Vikram; Shivakumar, Madhu; Subbanna, Shivakumar. (2019). Distinct functions of endogenous cannabinoid system in alcohol abuse disorders.. British journal of pharmacology, 176(17), 3085-3109. https://doi.org/10.1111/bph.14780
Explore the wider topic
- Physical vs Psychological Cannabis Dependence: What Science Actually Shows
- The Gap Between Cannabis Perception and Science: Why What We Believe Outpaces What We Know
- Cannabis Use Disorder: Am I Addicted? Self-Assessment Guide
- Cross-Addiction After Quitting Weed: When One Habit Replaces Another
- Is Weed Addictive? What the Research Actually Shows
- Is Cannabis Addictive? What the DSM-5 and Brain Science Say
- Quitting Weed and Alcohol Together: What to Know About Dual Cessation
- Is Rehab Necessary for Weed? An Honest Assessment
- Signs You May Have Cannabis Use Disorder: An Honest Self-Assessment
- Weed Vape Pen Addiction: Why Vaping Makes It Harder to Quit